The development of biologic DMARDs has ushered in a new therapeutic era based on improved knowledge of the pivotal roles of pro-inflammatory cytokines (e.g., tumor necrosis factor [TNF]-α and several interleukins [ILs], such as IL-6 and IL-1beta) in RA [2,3]. The gene discussed is TNF; the disease is rheumatoid arthritis.